Stereotactic Radiosurgery for Vestibular Schwannomas: Reducing Toxicity With 11 Gy as the Marginal Prescribed Dose.
dose de-escalation
efficacy and safety
stereotactic radiosurgery (SRS)
toxicity
vestibular schwannomas (VS)
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
08
2020
accepted:
29
09
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
11
2020
Statut:
epublish
Résumé
Stereotactic radiosurgery (SRS) is a common treatment option for vestibular schwannomas. Historically, a dose de-escalation of the marginal prescribed dose from 16 Gy to 12-13 Gy has been done to limit toxicity without reducing local control (LC). We aimed to retrospectively report outcomes of Linac-based SRS for vestibular schwannomas treated with different doses. Included in the study were 97 stage 1 (1%), 2 (56%), 3 (21.5%), and 4 (21.5%) vestibular schwannomas treated with Linac-based (Novalis Following SRS, LC at 3, 5, and 10 years was 100%, 98.4%, and 95.6%, respectively [100% for those with ≤ 13 Gy as the marginal prescribed dose (NS)]. Toxicity to the trigeminal nerve was reported in 7.2% of cases (3.3% and 0% for transient and permanent toxicity for 11 Gy). The marginal prescribed dose was the only significant predictive factor in univariate and multivariate analysis (HR = 1.77, 95% CI = 1.07-3.10, p = 0.028). Toxicity to the facial nerve was reported in 6.2% of cases. The marginal prescribed dose was again the only significant predictive factor in univariate and multivariate analysis (HR = 1.31, 95% CI = 0.77-2.23, p = 0.049). Linac-based SRS for stages 1-3 vestibular schwannomas provides excellent outcomes: a 10-year LC rate of over 95%, with a permanent facial or trigeminal toxicity rate of under 5%. A marginal prescribed dose of 11 Gy seems to decrease nerve toxicity and facial toxicity in particular, without reducing LC. Prospective studies with longer follow-up are needed.
Sections du résumé
BACKGROUND
BACKGROUND
Stereotactic radiosurgery (SRS) is a common treatment option for vestibular schwannomas. Historically, a dose de-escalation of the marginal prescribed dose from 16 Gy to 12-13 Gy has been done to limit toxicity without reducing local control (LC). We aimed to retrospectively report outcomes of Linac-based SRS for vestibular schwannomas treated with different doses.
METHODS
METHODS
Included in the study were 97 stage 1 (1%), 2 (56%), 3 (21.5%), and 4 (21.5%) vestibular schwannomas treated with Linac-based (Novalis
RESULTS
RESULTS
Following SRS, LC at 3, 5, and 10 years was 100%, 98.4%, and 95.6%, respectively [100% for those with ≤ 13 Gy as the marginal prescribed dose (NS)]. Toxicity to the trigeminal nerve was reported in 7.2% of cases (3.3% and 0% for transient and permanent toxicity for 11 Gy). The marginal prescribed dose was the only significant predictive factor in univariate and multivariate analysis (HR = 1.77, 95% CI = 1.07-3.10, p = 0.028). Toxicity to the facial nerve was reported in 6.2% of cases. The marginal prescribed dose was again the only significant predictive factor in univariate and multivariate analysis (HR = 1.31, 95% CI = 0.77-2.23, p = 0.049).
CONCLUSION
CONCLUSIONS
Linac-based SRS for stages 1-3 vestibular schwannomas provides excellent outcomes: a 10-year LC rate of over 95%, with a permanent facial or trigeminal toxicity rate of under 5%. A marginal prescribed dose of 11 Gy seems to decrease nerve toxicity and facial toxicity in particular, without reducing LC. Prospective studies with longer follow-up are needed.
Identifiants
pubmed: 33194765
doi: 10.3389/fonc.2020.598841
pmc: PMC7659960
doi:
Types de publication
Journal Article
Langues
eng
Pagination
598841Informations de copyright
Copyright © 2020 Dupic, Urcissin, Mom, Verrelle, Dedieu, Molnar, El-Ouadih, Chassin, Lapeyre, Lemaire, Biau and Khalil.
Références
J Radiat Res. 2014 Mar 1;55(2):288-92
pubmed: 23979079
J Neurooncol. 2014 Jan;116(1):187-93
pubmed: 24142200
Clin Oncol (R Coll Radiol). 2014 Jun;26(6):309-15
pubmed: 24636634
J Radiat Res. 2014 Mar 1;55(2):351-8
pubmed: 24142966
J Neurosurg. 2006 Nov;105(5):657-61
pubmed: 17121123
Otolaryngol Head Neck Surg. 1985 Apr;93(2):146-7
pubmed: 3921901
Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e503-9
pubmed: 21665381
Otolaryngol Head Neck Surg. 2010 May;142(5):677-81
pubmed: 20416455
Prog Neurol Surg. 2008;21:222-227
pubmed: 18810223
Acta Neurochir (Wien). 2014 Jun;156(6):1121-3
pubmed: 24682634
Neurosurgery. 2019 Sep 1;85(3):409-414
pubmed: 30169695
Acta Neurochir (Wien). 2017 Jun;159(6):1013-1021
pubmed: 28409393
Int J Radiat Oncol Biol Phys. 2003 Aug 1;56(5):1390-6
pubmed: 12873685
Neurosurgery. 2001 Dec;49(6):1299-306; discussion 1306-7
pubmed: 11846928
Br J Neurosurg. 2015;29(5):678-84
pubmed: 25968327
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1352-5
pubmed: 21700400
J Clin Neurosci. 2010 May;17(5):556-60
pubmed: 20227884
Radiother Oncol. 2013 Feb;106(2):169-74
pubmed: 23219253
Sci Rep. 2020 Jun 9;10(1):9309
pubmed: 32518238
Neurol India. 2009 May-Jun;57(3):257-63
pubmed: 19587464
Arch Otolaryngol Head Neck Surg. 2004 Feb;130(2):216-20
pubmed: 14967754
Clin Neurol Neurosurg. 2015 Nov;138:72-7
pubmed: 26282911
J Laryngol Otol. 2013 Aug;127(8):739-43
pubmed: 23866680
Radiat Oncol. 2017 Apr 21;12(1):68
pubmed: 28427410
J Neurosurg. 2001 Jan;94(1):7-13
pubmed: 11147901
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2041-6
pubmed: 21531086
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):721-8
pubmed: 26960748
South Med J. 1991 Nov;84(11):1327-33
pubmed: 1948217
Int J Radiat Oncol Biol Phys. 2011 Aug 1;80(5):1485-91
pubmed: 20708852
J Neurosurg. 2001 Jan;94(1):142-4
pubmed: 11147889
Int J Radiat Oncol Biol Phys. 2013 Feb 1;85(2):329-34
pubmed: 22704983